The California-based biotech company's quarterly revenue rose 9% from a year earlier to $9.9 billion, which beat the average ...
StockStory.org on MSN
AMGN Q4 deep dive: Product portfolio expansion and pipeline progress drive outlook
Biotech company Amgen (NASDAQ:AMGN) in Q4 CY2025, with sales up 8.6% year on year to $9.87 billion. The company’s full-year ...
The Manila Times on MSN
Amgen's Q4 results beat expectations, shares rise modestly
AMGEN on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations, sending its shares modestly higher as the company continues to express confidence in ...
Short- and long-acting bronchodilators are inhaled medications that can be used separately or in combination to manage COPD.
Taking l-theanine daily for a short period is generally safe, although not enough research has been done on its long-term use.
Menopause clinics across the U.S. are hearing from women who are having trouble filling prescriptions for estrogen patches, a common hormone replacement therapy.
Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results